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Executive Summary
Industry & Business Overview 
Korian SA is the European Leader of Elderly Care. It operates at all the levels of dependency, from home care, assisted living, nursing homes and specialized clinics. It is
currently present in 4 countries: France, Germany, Italy and Belgium.
The Elderly Care market shows very robust growth trends. It is estimated that the population over 80 in Europe will increase by a CAGR of 2.4% over the next 15 years.
Furthermore, the prevalence of elderly-related diseases (such as Alzheimer’s) will further drive the demand for nursing homes and professionalized nursing care.
This market is highly fragmented, with considerable economies of scale. This means that M&A can further drive growth, through the acquisition of smaller operators. Finally,
Korian operates in a non-cyclical industry, which ensures stability of cash flows and good performance of the buyout regardless of economic conditions.
Investment Thesis
Consolidation of smaller operators, in a highly fragmented market
Internationalization to Sweden, a shifting market with opportunities for private operators
Operational Turnaround in Germany, addressing the staffing problem through Korian’s international network 
Real Estate Portfolio optimization, and capital shift to care provision, Korian’s core business
Value Creation
Topline growth of 10% CAGR, with a network expansion in the countries where Korian operates of 23,000 beds in 310 facilities. Acquisition multiples at 5-7x (confirmed
with recent transactions) ensures multiple arbitrage, while economies of scale and implementation of Korian’s operating efficiency an expansion of EBITDA of bolt-ons.
Acquisition of Vardaga, a leading Swedish Nursing Home operator and part of the Healthcare Group Ambea. This will mean an additional 79 facilities, and this acquisition
represents a natural fit for both businesses, as Vardaga can take advantage of Korian’s know-how in the shift from outsourcing to private for-profit operation of nursing
homes, while Korian has access to one of the markets with highest daily rates, most public contribution to healthcare and highly favorable demographics.
A decline in occupancy rates for Germany nursing homes has been driven by a staff shortage of nurses. By implementing our strategy of hiring professionals abroad, we
are going to improve occupancy rates and profitability in this geography.
Through optimization of Korian’s Real Estate Portfolio, we will free capital which can be deployed in the core business of providing care to senior citizens. We are
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Valuation Summary
In our view, an EV/EBITDA multiple of 11.5x values Korian fairly. This multiple is in-line with precedent transactions in the industry, specifically of large, multi-country operators
(Casa Reha, Domus Vi, Alloheim).
This implies a premium of 20% on the current share price, and a valuation above the trading multiple over the last 5 years for Korian.
Analyzing multiples across the cycle for the peer group, we also conclude that current trading multiples are below historical levels, so we are confident this is a good entry
point and that an 11.5x entry multiple is an accurate valuation of Korian.
Sources of funds: 
Purchase price of €5070.4M, EBITDA of €437.0M and entry multiple of 11.5x, and including pipeline adjustments of €45.3M. Total fees of €227.7M
Uses of funds: 
In-line with discussions with BNP Leveraged Finance team, leverage of 7.5x and a bullet structure that allows higher investment in Korian’s expansion. 
Composed by €2,401.3M of senior debt and €873.9M of subordinated debt. 
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Company Overview | Business Model
Korian presents a “one-stop shop” solution for seniors, by offering a range of complementary services adapted to every stage of ageing.
GERMANY
#1
29% of total revenue
BELGIUM
#2
9% of total revenue
FRANCE
#1
53% of total revenue
ITALY
#2









1st in Europe in senior care services
LONG-TERM CARE NURSING HOMES ASSISTED LIVING FACILITIES
SPECIALIZED CLINICS (1)HOME CARE NETWORKS
These clinics are designed for people who need
complex post-operative care or who suffer from
slowly progressive or chronic illness, and that can
no longer be treated at home. Short-term
personalized care is provided to each patient to
help them recover as much of their capabilities so
they can return to their homes.
Developing area, capable of providing ongoing
and coordinated care to patients suffering from a
serious, acute or chronic illness. Both hospital and
nursing assistance are provided at the patient’s
place of residence, as an alternative to
hospitalization. These services cover the full range
of patient needs.
Independent living is combined with continuously
available assistance and personalized care.
Individual apartments are equipped to provide the
greatest possible independence, while ensuring
safety and security. Additional services provided
consist of catering, laundry, sauna and spa,
geriatric sports or social activities.
Designed to permanently accommodate
dependent elderly people, who have complex and
costly care requirements. It is offered a tailored
care to each resident’s degree of dependency,
with the maximum level of comfort and also other
services. Moreover, leisure activities are also
available to stimulate social interaction
Korian offers a broad range of services for the elderly, regardless of their age, health
requirements and other needs.
At the beginning, Korian solely operated nursing homes and
specialized clinics. Only recently it started developing its













BREAKDOWN OF REVENUE BY ACTIVITY 
Korian has been adding value through a joined-up approach, by connecting the different activities at local
level to leverage its asset base.
Source: Company Reports
(1) Exist only in France and Italy and represent around 1/3 of revenues of both countries.
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In 2016, the Group kept 
pursuing its growth strategy by 
opening new facilities in all four 
countries and by acquiring 
leading operators in German 
and Belgian markets.






Several acquisitions were 
undertaken in the French market, 
but to strengthen its leadership, 
Suren acquired Medidep, which 
operated nearly 7,500 beds.
Company Overview | Korian’s History
Korian has been successful in expanding its network, as represented by the number of beds’ CAGR of 18% in the last 10 years.
OCT ‘05
Medidep
The Group started looking for new growth 




Suren was founded in 
France with the 
merger of Finagest
and Sérience. The 
Group was then 
determined to focus 
on operating its 
nursing homes and 
specialized clinics.
MAR ‘03
Korian acquired the 2nd
largest Italian operator - 7 
facilities with 909 beds.
APR ‘07
Important deal that enabled 
Korian to enter the promising 
German market. Acquired 26 








exposure to a vast 
network in France, 












THE CREATION OF A LEADER THE EUROPEAN EXPANSION BEGINS ACCELERATION OF THE INTERNATIONAL EXPANSION
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Korian reached a leading 
position in Germany with the 
acquisition of 77 facilities with 
10,150 beds.
13,800 beds 23,880 beds 72,000 beds
MAR ‘13
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Due to its size and reputation, Korian is in a privileged position to take advantage of the favorable market conditions.
▪ With its critical mass, Korian offers both the brand recognition and visibility, which are essential to maintain a good relationship with administrative authorities and in
recruiting quality personnel.
▪ Significant cost synergies are generated by having a structured management to monitor the network of facilities and ensure a centralized management of support
functions.
▪ Its dense geographic network facilitates relations with local administrative authorities and logistics (relations with headquarters, partnerships and service providers).
▪ Tailored modern, well-equipped and well-maintained facilities, most often in urban centers and medical approach focused on high value-added services for patients.
1
PRICING POWER (1)
Regional business - pricing power highly dependent on the supply in that 
community and the competitors’ pricing.
Trade-off between higher tariffs and higher occupancy rates.
(1) More details on this topic are provided in the Industry Overview section of this presentation.





















Geographical Reach (# of countries)
2-3 4-5 >5
HOW DOES KORIAN ATTRACT CUSTOMERS?
▪ It is present in most urban centers, operating in quality facilities.
▪ Known brand, increased referral.
▪ Korian’s business model offers a complete continuum in the elderly services
which has the advantages of easily gaining client trust and also creating a
unique client attraction channel.
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2011 2012 2013 2014 2015 2016
Company Overview | Financials (1/7)
Revenue growth has relied heavily in acquisitions, visible with the steadily decreasing organic growth rate since 2011.
Revenues 1,015 1,108 1,371 2,222 2,579 2,987
% growth - 9.2% 23.7% 62.1% 16.1% 15.8%
Organic growth 5.4% 4.5% 4.1% 3.6% 2.4% 3.8%
COGS
64 71 93 173 212 236
6.3% 6.4% 6.8% 7.8% 8.2% 7.9%
Personnel expenses
480 531 656 1062 1267 1505
47.3% 47.9% 47.9% 47.8% 49.1% 50.4%
External expenses
183  188  205  298  326  353  
18.0% 16.9% 15.0% 13.4% 12.6% 11.8%
Taxes and duties
40,224 44,24 45,223 75,144 95,134 96,661
4.0% 4.0% 3.3% 3.4% 3.7% 3.2%
EBITDAR 247  275  370  614  678  796  
mg. 24.4% 24.8% 27.0% 27.6% 26.3% 26.7%
Rents
125  138  191  299  338  375  
12.4% 12.4% 14.0% 13.4% 13.1% 12.6%
EBITDA 122  137  179  315  340  421  
mg. 12.0% 12.4% 13.1% 14.2% 13.2% 14.1%
Depreciation 37  45  63  99  124  156  
Other operating income/expense (5)  (6)  (16)  (35)  (37)  (25) 
OPERATING PROFIT 79  87  100  181  179  241  
mg. 7.8% 7.8% 7.3% 8.2% 6.9% 8.1%
Net financial costs 33  34  45  74  65  123  
EBT 46  53  56  107  114  118  
mg. 4.6% 4.7% 4.1% 4.8% 4.4% 3.9%
Income Tax (20) (27) (24) (43) (53) 16
Net Profit 25 26 31 65 61 133
mg. 2.4% 2.3% 2.3% 2.9% 2.4% 4.5%
Avg Occupancy Rates 95.0% 89.0% 92.0% 93.3% 92.4% 90.7%
# of beds 23,808 34,724 34,094 57,058 59,715 81,186
Revenue CAGR11-16 24%
Visible focus on acquisitions, as organic growth* has been
decreasing since 2009. Even if a growth of 3-5% it is still a
remarkable achievement, meaning that the company is increasing
its market presence by exploiting its current assets. To revert this
alarming trend, CEO Yann Coleou was replaced by Sophie
Boissard. The rebound in 2016 is due to the later’s focus of growing
organically.
▪ 2013: acquisition of Curanum, a German operator with 10,000
beds - first major acquisition made outside of France.
▪ 2014: “merger of equals” with rival Medica (22.800 beds),
creating the largest provider of elderly care in France.
▪ 2015: growth driven by acquisitions made in all four countries,
with a higher contribution coming from the ones made in
Germany (2,018 beds).
▪ 2016: Germany and Belgium were the main drivers of growth with
the opening of 590 beds in 6 new facilities in Germany and the
opening of 180 beds in Belgium. The company also acquired
Casa Reha in Germany (10,200 beds) and Foyer de Lork in
Belgium (1,500 beds).
*Organic Growth comprehends revenue increase from: mature facilities, restructured 
facilities, Greenfields and acquisitions in the portfolio for more than 1 year.
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Korian has a medium-high fixed cost base. 
2011 2012 2013 2014 2015 2016
Company Overview | Financials (2/7)
Korian has a considerable high fixed cost base, with high staff requirements and rents which correspond to c. 60% of revenues. 
Costs
▪ COGS and external expenses have been decreasing since
2015/2016 due to the creation of multi-country contracts to
obtain hygiene and cleaning products, office supplies and
equipment.
➢ Korian spent 8,200€ per bed in 2016, comparing to
6,800€ spent by Orpea, pointing that there is room for
improvement.
➢ External expenses’ incredible reduction since 2011 in line
with number of beds increase, showing the scalability
potential of supply contracts.
▪ Personnel expenses represent the biggest component of Korian’s
cost base, due to high requirements in terms of nurses, doctors
and other professionals.
➢ Increase in 2015 due to the impact of the harmonization
costs, which brought to an increase of over 1.7% in the
wages of 6000 Medica employees and an increase of over
1/3 in the end year bonuses of Korian employees.
➢ In 2016 there were staff shortage and wage inflation in
Germany, increasing the staff costs.
▪ Taxes and duties refer to taxes related to property and operating
licenses.
Revenues 1,015 1,108 1,371 2,222 2,579 2,987
% growth - 9.2% 23.7% 62.1% 16.1% 15.8%
Organic growth 5.4% 4.5% 4.1% 3.6% 2.4% 3.8%
COGS
64 71 93 173 212 236
6.3% 6.4% 6.8% 7.8% 8.2% 7.9%
Personnel expenses
480 531 656 1062 1267 1505
47.3% 47.9% 47.9% 47.8% 49.1% 50.4%
External expenses
183  188  205  298  326  353  
18.0% 16.9% 15.0% 13.4% 12.6% 11.8%
Taxes and duties
40,224 44,24 45,223 75,144 95,134 96,661
4.0% 4.0% 3.3% 3.4% 3.7% 3.2%
EBITDAR 247  275  370  614  678  796  
mg. 24.4% 24.8% 27.0% 27.6% 26.3% 26.7%
Rents
125  138  191  299  338  375  
12.4% 12.4% 14.0% 13.4% 13.1% 12.6%
EBITDA 122  137  179  315  340  421  
mg. 12.0% 12.4% 13.1% 14.2% 13.2% 14.1%
Depreciation 37  45  63  99  124  156  
Other operating income/expense (5)  (6)  (16)  (35)  (37)  (25) 
OPERATING PROFIT 79  87  100  181  179  241  
mg. 7.8% 7.8% 7.3% 8.2% 6.9% 8.1%
Net financial costs 33  34  45  74  65  123  
EBT 46  53  56  107  114  118  
mg. 4.6% 4.7% 4.1% 4.8% 4.4% 3.9%
Income Tax (20) (27) (24) (43) (53) 16
Net Profit 25 26 31 65 61 133
mg. 2.4% 2.3% 2.3% 2.9% 2.4% 4.5%
Avg Occupancy Rates 95.0% 89.0% 92.0% 93.3% 92.4% 90.7%
# of beds 23,808 34,724 34,094 57,058 59,715 81,186
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2011 2012 2013 2014 2015 2016
Company Overview | Financials (3/7)
Visible difficulty in integrating Medica, as shown by the reduced EBITDAR margins since 2014.
Profitability
▪ After the merger with Medica in 2014, Korian had some difficulty
in integrating it. This diversion of focus allied to several
acquisitions of usually less efficient facilities in the four countries
in 2015, resulted in decreasing EBITDAR margins for the group.
▪ In 2016, the EBITDA margin improvement was due to rent
negotiations that enabled the company to make some savings.
▪ Other operating income/expense refers to gains or losses with
acquisitions and disposals.
▪ Net financial costs increased significantly in 2016 due to new
debt issuing: credit facility signed and Euro Commercial Paper
program. As a result, EBT margin decreased in 2016.
▪ Korian was not subject to income tax in 2016, due to changes in
French regulation and the increase in deferred taxes, in line with
the France 2020 Tax Plan. As a result, the profit margin
increased significantly in 2016 to 4.5%.
Revenues 1,015 1,108 1,371 2,222 2,579 2,987
% growth - 9.2% 23.7% 62.1% 16.1% 15.8%
Organic growth 5.4% 4.5% 4.1% 3.6% 2.4% 3.8%
COGS
64 71 93 173 212 236
6.3% 6.4% 6.8% 7.8% 8.2% 7.9%
Personnel expenses
480 531 656 1062 1267 1505
47.3% 47.9% 47.9% 47.8% 49.1% 50.4%
External expenses
183  188  205  298  326  353  
18.0% 16.9% 15.0% 13.4% 12.6% 11.8%
Taxes and duties
40,224 44,24 45,223 75,144 95,134 96,661
4.0% 4.0% 3.3% 3.4% 3.7% 3.2%
EBITDAR 247  275  370  614  678  796  
mg. 24.4% 24.8% 27.0% 27.6% 26.3% 26.7%
Rents
125  138  191  299  338  375  
12.4% 12.4% 14.0% 13.4% 13.1% 12.6%
EBITDA 122  137  179  315  340  421  
mg. 12.0% 12.4% 13.1% 14.2% 13.2% 14.1%
Depreciation 37  45  63  99  124  156  
Other operating income/expense (5)  (6)  (16)  (35)  (37)  (25) 
OPERATING PROFIT 79  87  100  181  179  241  
mg. 7.8% 7.8% 7.3% 8.2% 6.9% 8.1%
Net financial costs 33  34  45  74  65  123  
EBT 46  53  56  107  114  118  
mg. 4.6% 4.7% 4.1% 4.8% 4.4% 3.9%
Income Tax (20) (27) (24) (43) (53) 16
Net Profit 25 26 31 65 61 133
mg. 2.4% 2.3% 2.3% 2.9% 2.4% 4.5%
Avg Occupancy Rates 95.0% 89.0% 92.0% 93.3% 92.4% 90.7%
# of beds 23,808 34,724 34,094 57,058 59,715 81,186
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Company Overview | Financials (4/7)
Decreasing tariffs in the post-acute care and a staff shortage are decreasing margins in Italy and Germany, respectively. 
2011 2012 2013 2014 2015 2016
713  762  766  1 323  1 536  1 572  
8,6% 6,9% 0,5% 72,9% 16,1% 2,4%
24,6% 24,6% 26,3% 27,8% 26,7% 27,2%
139  157  414  476  519  852  
16,9% 13,2% 164% 15,1% 9% 64,2%
26% 27,6% 29,8% 30,2% 27,7% 27,0%
164  190  192  266  306  303  
17,8% 16,1% 1% 38,5% 15,2% -1,1%*




























Caused by the Medica merger that 
brought increased personnel expenses 
and heavy losses at a recently acquired 
facility.
Given the importance of the German market for Korian (29% of revenues), we will try to assess and 
mitigate the impact of the staff shortage to bring margins back to the levels prior to 2015.
Why is Italy so different?
▪ Revenue down in 2016 due to the
planned shutdown of 4 facilities.
▪ There is a focus on post-acute clinics
(c.30% of revenues), which require more
specialized professionals, and whose
price is started declining due to
Government budget constraints.
➢ In 2013, the cost per employee in
Italy was 30% higher than in
Germany.
Germany’s higher EBITDAR margin
potential is due to two reasons:
▪ Nursing Homes and Assisted Living
offered in shared facilities.
▪ No specialized clinics.
A closer look on profitability by country:
Staffing Problem in Germany
Difficulty to find qualified nurses due to
the low number of graduations in this field,
resulting in higher personnel expenses
and lower occupancy rates given the
unavailability of staff.
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Company Overview | Financials (5/7)
Korian’s asset base mainly composed by Goodwill, followed by Intangible Assets and Property, Plant and Equipment.
2011 2012 2013 2014 2015 2016
Non-Current Assets
▪ Goodwill represents the largest part of Korian’s assets, related to
previous acquisitions.
▪ Intangible fixed assets are mainly composed by licenses to operate
nursing homes, recorded at €1,599M.
▪ Property, Plant and Equipment is mainly composed by Land &
Buildings, recorded at €1,322M.
➢ The net value of PPE held under financial leases was €724M,
totaling a commitment of €719M.
➢ There are also €3,794M of commitments to operating leases
which are not capitalized in the balance sheet.
▪ Korian’s Real Estate portfolio is largely concentrated in France, where
Korian’s legacy status and market knowledge allow for higher asset
ownership.
➢ Korian owns 96 buildings (14% of its facilities), which are
valued at €1,280M.
➢ Korian rents 614 buildings (86% of its facilities), with length of
rentals ranging from 9 to 27 years.
Goodwill 688  667  749  1 618  1 707  2 175  
Intangible fixed assets 684  658  670  1 713  1 701  1 718  
Property, Plant and Equipment 405  387  557  1 165  1 296  1 670  
Other 58  156  72  142  180  217  
Non-current assets 1,834  1,867  2,048  4,638  4,884  5,780  
Inventories 3  3  4  7  8  10  
Trade recivables 92  78  88  143  154  168  
Other receivables 119  121  136  232  200  225  
Financial instruments 0  0  0  0  0  2  
Cash and cash equivalents 41  163  52  235  519  310  
Current assets 255  364  280  618  881  714  
Total assets 2,089  2,232  2,328  5,256  5,765  6,494  
Share capital 164  170  174  395  397  401  
Premiums 277  285  293  917  927  842  
Retained earnings 262  260  278  591  598  781  
Non-controlling interests 20  21  23  -2  11  14  
Total shareholders' equity 723  735  769  1,902  1,934  2,037  
Borrowings 623  665  714  1,638  2,069  2,442  
Other 276  294  284  753  810  872  
Non-current liabilities 898  959  997  2,391  2,878  3,314  
Trade payables 114  124  136  239  228  250  
Borrowings 37  60  59  78  95  183  
Other 316  354  367  646  630  710  
Current liabilities 468  537  562  963  953  1,143  
Total liabilities 1,366  1,497  1,559  3,354  3,831  4,457  
Total equity + liabilities 2,089  2,232  2,328  5,256  5,765  6,494  
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Company Overview | Financials (6/7)
Due to its business characteristics, Korian as low Working Capital Requirements, averaging 0.12% of revenues.
2011 2012 2013 2014 2015 2016 Working Capital Requirements
▪ Korian has around -€72m of working capital requirements, due to
higher number of days payable versus days receivable.
➢ Working capital investments in the last 5 years have been very
low, averaging a total of 0.12% of revenues.
Leverage
▪ Korian’s debt base is diversified across multiple debtholders and
financing sources:
➢ €650M available on a revolving credit facility;
➢ €838M in real estate debt, consisting mainly of finance leases
with long maturities;
➢ €1,021M in bonds placed with private investors;
➢ €50M in commercial paper;
➢ €58M in other borrowings.
▪ Average cost of debt (excluding leases) was 2.97% in 2016.
▪ Debt secured with collateral, a mortgage or lease accounted for
15.6% of gross borrowings.
▪ Korian’s restated(1) Net debt to EBITDA was 3.2x (covenant is 4.5x)
(1) = (Net Debt – Real Estate Debt) / (EBITDA – (6.5% x Real Estate Debt)) 
Net Debt To EBITDA 5.04x 4.04x 2.10x 4.12x 4.81x 5.48x
Days Payable 41.17 40.77 36.17 39.20 32.29 30.61
Days Receivable 32.91 26.21 23.52 23.42 21.83 20.56
2011 2012 2013 2014 2015 2016
Goodwill 688  667  749  1 618  1 707  2 175  
Intangible fixed assets 684  658  670  1 713  1 701  1 718  
Property, Plant and Equipment 405  387  557  1 165  1 296  1 670  
Other 58  156  72  142  180  217  
Non-current assets 1,834  1,867  2,048  4,638  4,884  5,780  
Inventories 3  3  4  7  8  10  
Trade recivables 92  78  88  143  154  168  
Other receivables 119  121  136  232  200  225  
Financial instruments 0  0  0  0  0  2  
Cash and cash equivalents 41  163  52  235  519  310  
Current assets 255  364  280  618  881  714  
Total assets 2,089  2,232  2,328  5,256  5,765  6,494  
Share capital 164  170  174  395  397  401  
Premiums 277  285  293  917  927  842  
Retained earnings 262  260  278  591  598  781  
Non-controlling interests 20  21  23  -2  11  14  
Total shareholders' equity 723  735  769  1,902  1,934  2,037  
Borrowings 623  665  714  1,638  2,069  2,442  
Other 276  294  284  753  810  872  
Non-current liabilities 898  959  997  2,391  2,878  3,314  
Trade payables 114  124  136  239  228  250  
Borrowings 37  60  59  78  95  183  
Other 316  354  367  646  630  710  
Current liabilities 468  537  562  963  953  1,143  
Total liabilities 1,366  1,497  1,559  3,354  3,831  4,457  
Total equity + liabilities 2,089  2,232  2,328  5,256  5,765  6,494  
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Net Profit/(Loss) 25 26 31 65 61 133
Net depreciation, amortisation and provisions 32 48 58 98 146 160
Deferred taxes -1 -2 -5 6 1 -73
Gain or loss at fair value and non cash items 1 1 -1 -1 -1 -6
Gain on disposal of assets 2 -15 1 2 2 -0
Cash flow after cost of net debt 59 59 85 169 209 215
Elimination of acquisition costs of securities 3 0 5 1 5 1
Elimination of net interest paid 32 32 43 68 52 88
Change in the working capital requirement 4 35 -14 8 -21 4
Net cash generated from operations 98 126 119 247 245 307
As a % of Revenues 9.7% 11.4% 8.6% 11.1% 9.5% 10.4%
Impact of changes in scope (acquisitions) -83 -22 -83 -35 -75 -392
Impact of changes in scope (disposal) 17 8 67 5 4 3
Payment for PP&E and intangible assets -79 -73 -121 -113 -140 -160
Payment for other financial investments -4 -2 1 3 3 1
Proceeds from disposal of non current assets 40 57 72 7 16 40
Net cash from/(used in) investing activities (108) (31) (64) (132) (193) (509)
Free Cash Flow (9) 95 54 115 51 (201)
Increase in financial liabilities 100 132 185 1,417 503 200
Repayment of financial liabilities -55 -67 -299 -1,243 -184 -89
Net interest paid -32 -32 -43 -76 -52 -97
Dividends paid to shareholders of the parent -19 -5 -8 -47 -35 -29
Net cash from/(used in) financing activities 2 27 (165) 68 230 (14)
Change in cash position (8) 122 (111) 184 281 (216)
2011 2012 2013 2014 2015 2016
Company Overview | Financials(7/7)
Korian generates a high cash flow from operations, around 10% of revenues.
Casa Reha (€291m) was the largest acquisition in the period, in
large part due to the high level of real estate.
Korian underwent a major debt restructuring in 2014, in-line
with the internal restructuring following the merger with Medica
Korian has generated positive free cash flows, and tends to
reinvest the majority of the proceeds into the business
Cash Generation
▪ Korian is a highly cash generative business:
➢ Cash generated by operations has been 9-11% of
Revenues, with a growth in line with the expansion both at
greenfield and acquisition levels.
➢ Even accounting for maintenance capital expenditures
(2.5-3% of revenues), cash generation is still at a healthy
6-8%.
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Company Overview | Share Ownership











Other Significant Asset Manager positions in Korian
Asset Manager # shares % of outstanding
Threadneedle 2.22m 2.74%
Norges Bank 1.58m 1.95%
Exane 1.37m 1.70%
Dimensional Fund Advisors 1.06m 1.31%
The Vanguard Group 1.01m 1.25%
BNP Paribas 832.63k 1.03%









Korian Share Price Performance over last 5 years
Other Share Ownership
▪ Only disclosed information on CEO Sophie Boissard, with 388 shares by Dec-16.
▪ Board of Directors as a whole owns 14,667 shares in Korian (0.018% of float)
▪ French employees own a total of 130,000 shares in Korian, as part of a program
initiated at the time of the merger with Medica. c. 0.2% of total float.
Share Price Information
Average daily volume 135538 shares (€3,776m) 
High (12 months) € 32.13
Low (12 months) € 23.76
1-year return 7.03%
YTD return 0.05%
Market cap. €2.256m 
Number of outstanding shares 80.982.343 shares
Tickers
Kori FP (Bloomberg)
FR00 10 386 334 (ISIN)
KORI.PACode (Reuters) 
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Approximately 1% of GDP is spent on long-term nursing care on average across Europe.
Industry Overview | General Overview (1/2)
The European nursing home market lacks beds to support the expected booming demand in the following years.
In the OECD 27 countries, the weight of long-term care is, on 
average, 12% of the total healthcare expenditure.
GLOBAL HEALTHCARE MARKET EUROPEAN NURSING HOME MARKET
Private organizations are crucial to prepare for the anticipated booming








The maturity of the nursing home market also varies across countries:
At the national level, the care home market can be broken down into three main types:
Licensed Free Market Outsourced
Belgium, France and Italy Germany, Spain and UK Finland, Norway and Sweden
Mature Consolidating Lagging




Population aged above 80 years old
By 2025, more than 20% of Europeans will be 65 or over.






Source: Company Reports, OECD, Analyst Reports
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TRENDS
Industry Overview | General Overview (2/2)
Social and demographic factors are sustaining the global Healthcare Market’s growth.
▪ Dementia (affects 50-70% of nursing homes residents) is increasing in every region of the world and it is expected to double every 20 years.
▪ Elders are typically entering care homes considerably later in life, residing for far shorter periods but requiring much more specialized care during their stay.
▪ Market is undergoing a period of expansion, largely driven by the private sector, and it is visible strong M&A activity.








Long-term care market expenditure vs. 
Korian's Revenue 















An ageing population represents the sustainability of revenues 
and the possibility of increasing occupancy rates.
Resilient business, although a shift to lower cost alternatives 
(e.g.: elders being cared for by their relatives) is possible.
Korian’s growth strategy has heavily relied on acquisitions, 
something expected to prevail.
Elders may be willing to pay a higher price, although Korian’s 
pricing power depends on the presence of local competitors.
This results in increased life expectancy and enhanced quality 
of life, which favors Korian’s home care segment.
IMPACT FOR KORIAN
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Total Market Value €18.1 B €26.7 B €6.6 B €5.3 B
# of beds 603,823 1,284,918 390,000 145,679
# of beds per 1000 
people aged >80
165 178 95 228
2015-30 CAGR 
population aged >80
1.6% 3.3% 2.2% 1.7%
Avg. daily fee 110 100 90 110
Avg. EBITDAR mg.(1) 22.1% 21.2% 15.6% 18.3%
BELGIUMITALYFRANCE
Industry Overview | France, Germany, Italy and Belgium 
























(% of market’s 
total capacity)
Main Trends: ▪ People aged 85+ are expected to
grow at an annual rate of 2.46% until
2035.
▪ 25,000-30,000 new beds will be
needed in the next 5-10 years.
▪ People aged 85+ are expected to
grow at an annual rate of 2.27% until
2035.
▪ The dependent elderly will increase
by 30% by 2022.
▪ Need for 200,000 beds over the next
years.
▪ People aged 85+ are expected to
grow at an annual rate of 2.36% until
2035.
▪ 4th highest life expectancy in OECD
countries, but consistently poorer
health indicators.
▪ People aged 85+ are expected to
grow at an annual rate of 1.90% until
2035.
▪ LTC facilities’ residents are expected
to grow by an average of 2,500
people per year until 2025, creating









































Source: Company Reports, UN, OECD, Analyst Reports
(1) of the industry, 
estimated based on 
information about peers
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BELGIUMITALYFRANCE
Industry Overview | France, Germany, Italy and Belgium 
Countries where Korian operates - regulatory framework and pricing dynamics.
GERMANY
Regulation The creation, transformation or
extension of a nursing home is subject
to the issuance of a license validated by
local authorities. The license cannot be
used to operate a facility until it has
been granted healthcare funding by the
relevant authorities.
Once operating licenses have been
obtained a facility can be opened, and
there is no limit for the number of beds.
The facilities are then subject to
external audits to assess if quality
standards are being met, with the
possibility to lose the license if not.
The Italian healthcare system is similar
to that of France, where facilities must
be licensed and accredited in order to
receive funding from the regulatory
authorities. Quality standards are set at
the regional level and must be met to
maintain accreditation.
The Regions are responsible for the
initial licensing, monitoring and quality
control of facilities. Licenses are issued
on the basis of regional healthcare
programs, taking into account the
population 65+ trend and are subject to









Treatment Rate - Set and paid directly
by the Regional Health Authority to the
facility in a single payment that
depends on the amount of medical care
provided at the facility based on the
facility’s projected annual budget.
Dependency Rate - Set, paid and
reviewed each year by the local
Department Council to support the
daily living assistance services based
on the dependency levels of the
facility’s residents.
Accommodation Rate - Set freely in a
“residence contract” between the
facility and all the new residents. Once
this contract is signed, rates cannot be
increased beyond the annual maximum
increase decided by the Minister of the
Economy and Finance.
Operators have to negotiate the
following components of their tariffs




These components are highly regulated
and paid by the local authorities. The
reimbursement is agreed on a case-by-
case basis depending on the level of
dependency of each patient.
Investment portion to cover rental and
associated charges is paid by the
resident. It is defined for a period of one
year and must be set in proportion to
the cost of rental, depreciation, interest
rates and investments.
Since the Constitutional Law on
Decentralization of 2001, the Regions
are exclusively responsible for all social
policies, including long-term healthcare.
Treatment Rate is funded by local
Regional Health Authority, it is highly
regulated and it is a direct
reimbursement of costs (no margin is
allowed).
Accommodation Rate is paid by the
resident and may be set freely in
Lombardy, Veneto, Lazio and Apulia
but is capped elsewhere. Korian is free
to determine it in every facility operated
in Italy.
Facilities are not free to set their own
tariffs. The regional governments
monitor rates and regulate annual
increases.
Medical care and dependency cost is
reimbursed in proportion to the
resident’s degree of dependency and
illness, as determined by the Katz
Index.
Accommodation rates can be
negotiated when the facility is
established, which are then indexed to
the consumer price index and any
increase beyond this must be applied
for and substantiated to get the
approval from the regional authorities.
NO / n.a. YES / n.a. NO / YES NO / n.a.
Flexibility to define
them? YES NO YES NO
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Investment Thesis
by Tiago Marques
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Investment Thesis
Korian, as the market leader, is in a unique position to implement a consolidating and integrating strategy.
▪ Given typical private ownership of smaller, less efficient facilities and the high market fragmentation, Korian has the opportunity to become the main market consolidator,
▪ There’s the opportunity to expand internationally, with Nordic countries being a tremendous opportunity,
▪ With the implementation of an effective integration plan, Korian can also take advantage of the opportunities to grow organically via greenfield investments.
2 Buy and build, nationally and internationally
▪ Improve the quality of the facilities with the refurbishment of 2,000-3,000 beds per year, which will support price increases in France and Italy, and will maintain quality
standards to avoid the lose of operating licenses.
▪ Given the strategical importance of Germany, we are going to mitigate its staff problem by hiring foreign personnel and work more closely with universities to avoid further
deterioration of occupancy rates.
▪ At group level there are several functions that are not consolidated yet and that could generate significant cost savings.
3 Operational improvements by increasing quality of service, hiring new personnel for Germany and by fostering synergies at group level
▪ Sell part of non-core real estate and bet on leasebacks taking advantage of partnerships with real estate companies already in place and use the proceeds to expand our
operations.
▪ Target an EBITDAR over rental expenses above 1.5x (current one is 2.13x). With a growing demand and supply deficit, we believe an expansive posture on this ratio will
not increase Korian’s risk significantly.
Optimize Real Estate strategy4
▪ Growing demand supported by favorable demographic trends, with an ageing population and longer life expectancy, accompanied by insufficient supply.
▪ Korian enjoys leading positions in four European countries that account for over 50% of all Europeans older than 75 and that are recovering from the past European crisis.
▪ Cash flow from operations above 70% of EBITDA, due to low working capital requirements and low maintenance capital expenditures.
Highly cash generative business in an industry with strong long-term fundamentals.1
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Value Creation Strategy
by Tiago Marques
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# Acquisitions France Germany Belgium Italy
Facilities 80 85 110 35
Beds 5,680 5,440 10,010 1,995
It is visible the feasibility of our strategy with the existence of many possible targets to acquire.
Value Creation Strategy | Consolidation
There is plenty of room for consolidation in the markets where Korian is, with a big portion of beds being operated by small players.
Our expansion strategy consists in strengthening Korian’s position in the four markets where it currently operates.
Opportunity for Bolt-on Acquisitions Bolt-on Acquisitions: Investment Plan
The four markets are characterized by a high level of fragmentation and a structural supply deficit.
Beds operated by small players.
Beds operated by private players:









37,189 340,815 37,731 50,700
Average facilities:
France Germany Belgium Italy
71 beds 64 beds 91 beds 57 beds
524 5,325 415 889
Facilities that can be acquired.
Assumptions
Average Daily Tariff (1) 110 100 110 90
Occupancy Rate 90% 89% 89% 85%
Average EBITDA Mg. (2) 7% 7% 7% 7%
EV/EBITDA Deal Multiple (1) 6 6 6 5
EV – Value of Operations (m) €1,08 €0,87 €1,37 €0,56
Real Estate Price (m) (3) €8,8 €8,2 €8,4 €7,9
Equipment Price (m) (4) €1,12 €1,12 €1,12 €1,12
(1) Based on Credit Suisse Industry Report
(2) Estimated based on several players in the sector (margins usually from 5% to 15% depending on the size of the player)
(3) Based on Kepler Cheuvreux’s cost estimations for a new facility, construction costs adjusted by country based on EC Harris Research “International Construction Cost Report”
(4) Based again on Kepler Cheuvreux’s cost estimations for equipment cost with assumed age adjustment of -70%.
Due to the high number of acquisitions per year, an investment in a 
M&A team will be made to plan and execute this strategy.
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Value Creation Strategy | Internationalization (1/4)
The Nordic region presents the best opportunity to expand in Europe due to its market dynamics and recent trends.
VISIBLE TENDENCY:
Slowing outsourcing market, mainly in Sweden. Companies shift from outsourcing
contracts towards building their own operations in this region, to avoid suboptimal
building structures and deliver a more efficient care.
SWEDEN FINLAND NORWAY DENMARKThere are also a lot of countries that Korian can expand to, and after a thorough
analysis, the conclusion is that the Nordic countries represent the best opportunity :
▪ funding of private healthcare sector by public funds
▪ encouragement of governments towards private investments
▪ need to create more beds
▪ existence of target companies well positioned in the market
▪ decelerating outsourcing market
Pop. Growth 80+ 
(2015-2040)
55% 61% 33% 72%
LTC beds per 
100 people 80+
25% 23% 19% 19%
Need of beds 
by 2030
45k 35k n.a. n.a.
Total Market Size
In billion €
7.8 2.7 3.5 2,4
Multi-year outsourcing contracts (5-10 years)
COMMON MODEL
Greater uncertainty over sustainability of revenues: in the end of contracts the
companies compete against each other for the contract renewal (competing in
prices, thus decreasing margins).
The slowdown of the outsourcing market enables companies to increase 
margins.



































27Investment Committee Paper January 25th, 2018
Value Creation Strategy | Internationalization (2/4)
Aleris and Vardaga represent good targets to implement our strategy, with significant market reach and exposure.
POSSIBLE TARGETS:
To gain immediate exposure to the Nordic region with a structured organization and a network in place, acquiring an already well-established player might be the
best option for us.
(Ambea’s Nursing Home division)
(1) The company operates in other segments, but we would only be interested in its Nursing Home division.
(2) In the private long-term care Nordic market (2016) - the private market represented 19% of the total long-term care Nordic market in terms of revenues.
(3) Whole group had revenues of SKR 10B (€ 1.04B; 1 SKR in EUR at 31/12/16 was 0.10461), and the nursing home division is assumed to represent 25% of revenues.
(4) It was assumed an EBITDA margin of 4%, according to Credit Suisse Research
EBITDA margin improvement as an opportunity: Vardaga and Aleris have an EBITDA margin of 5,5% and 4%, respectively. These values are quite low when compared with
Korian. But due to the decrease of the outsourcing model and with the integration in Korian’s supply chain, the margin is expected to increase.
Vardaga offers individual-focused healthcare and care services in special
residential nursing homes for the elderly. Vardaga is one of Sweden’s
largest private providers of elderly care services with approximately 75
nursing homes throughout Sweden, with 7,000 employees.
Aleris is one of Scandinavia's leading private health care companies. Its
services include hospitals and medical centers, child welfare, mental health
services, user-controlled personal assistance, elderly care and facilities for
the disabled. Aleris has around 11,000 employees in 350 facilities.
Segment Nursing Homes Nursing Homes (1)
Countries Sweden Sweden; Norway; Denmark
Beds 3,500 n.a.
Market Share (2) 6,9% 8,1%
Revenues 16 (€) 225.8 M 261.5 M (3)
EBITDA 16 (€) 12.5M 10.46 M (4)
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Value Creation Strategy | Internationalization (3/4)
Sweden represents the safest alternative for Korian to expand to the Nordic region, as its business model is becoming more compatible.
Why Sweden?
▪ Biggest Nordic market;
▪ Rapidly ageing population resulting in the highest need in terms of beds to be created;
▪ Enables Korian to assess carefully the adaptability of its business model to the market characteristics, and if
successful consider opportunities to expand to the other Nordic countries;
▪ Outsourcing market decelerating at a fast pace:
➢ Visible shift towards the construction of owned facilities, field in which Korian has a lot of experience and
know-how.
▪ Diversification in terms of funding and regulatory legislation.
▪ Acquisition of knowledge relative to the experience of Nordic companies to operate facilities in the most efficient way due to the outsourcing model. 
➢ Possibility for Korian to enhance this efficiency by integrating costs and by having an exclusive supply chain to all company.
HOW CAN AN EXPANSION TO THE NORDIC REGION BE ADVANTAGEOUS FOR KORIAN?
Target: Vardaga (Ambea’s Nursing Home division)
▪ Whole company is dedicated to nursing homes (our focus);
▪ Solid target with considerable experience in the market;
▪ This year Attendo made a deal with a similar profile by acquiring the home care division of the care company
Humana, showing that this type of deals can be made.
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Value Creation Strategy | Internationalization (4/4)
To take advantage of the slowdown in the outsourcing market, our expansion plan comprises as well greenfield investments in Sweden.
(€ M) Average situation




Average length: 24 months
Rental yield 4.5%
Source: Kepler Cheuvreux and Harris Research – International Construction Cost 
Report 
Source: Company Reports; Industry Reports








All facilities will be leased back, as such the development costs will be supported
by real estate companies with whom Korian has partnerships. Korian will only
support the equipment cost.
Why?
▪ The private market is not as fragmented as the previous countries(1);
▪ There are licenses available for new constructions;
▪ The government is encouraging private investments: both the outsourcing model and the number of public owned facilities is decreasing (in 2005 the
private owned facilities represented 10% of the Nursing Homes market and in 2015 it grew to 19%)(1);
▪ The rental yields are lower compared to the other countries, making more affordable the leaseback of facilities.
(1) More detail provided in Appendix: Internationalization (5/5)
Impact/CAPEX
1.44x
Greenfields Investment Plan Assumptions:
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Value Creation Strategy | Operational Turnaround (1/2)
With the renovation of facilities and the resolution of the German staffing problem, we believe profitability can be enhanced.
REFURBISHMENT OF FACILITIES
Restructure 
2,000 - 3,000 beds 
per year
With modern facilities, value for 
money perception increases 
resulting in a higher pricing 
power.
CAPEX per bed
c. 16,000 € 
Not only they are needed to comply with quality standards and 
avoid losing operating licenses, but also because to increase 
prices in France and Italy (where Korian is free to set the 
accommodation rates), the higher rate must be seen as 
reasonable, as there is a tradeoff between higher price and 
higher occupancy rate. 
STAFFING PROBLEM IN GERMANY
Occupancy rates in Germany stand at 85 - 90% due 
to unavailability of qualified nurses.
To mitigate this problem we plan to:
▪ Implement recruitment programs of apprentices;
▪ Implement a program to recruit qualified staff
abroad;
▪ Strengthen the local human resources network
with the creation of partnerships with universities.
To recruit abroad there are some countries that are worth our attention:
▪ South Korea is the one of the countries with more graduated nurses per
100,000 inhabitants (109), followed by Slovenia (77);
▪ Russia, Lithuania, Romania and Latvia are considered to be the lowest paying
countries in terms of nursing salary, which can provide us with the opportunity to
recruit personnel looking for better remuneration conditions;
▪ Austria and Switzerland are also good alternatives because the language is the
same and are close countries in cultural terms.
Total Impact on EBITDA / Total Capex (1)
1.52x
(1) The detailed analysis is provided in Appendix: Value Creation Strategy (1/2)
Annual Investment
€ 35 - 50 M
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Value Creation Strategy | Operational Turnaround (2/2)
We are able to deliver higher quality care at lower cost by leveraging our expertise and scale.
Korian can create more value by exploiting the synergies present in its own facilities. Resulting in:
It is a process that is already in place in the company and our strategy is to accelerate the









▪ Put in place long-term contracts with suppliers, taking advantage of our supply
chain specialized teams and its vast network.
▪ Stipulate regional and multi-country contracts to exploit the scale factor and
bring to the table more negotiating power.
▪ Shift purchasing process from wholesalers to manufacturers.
▪ Reinforce our Engagement & Control process which will contribute to avoid
















Impossibility to tighten long-term regional contracts due to suppliers’
incapacity to commit to the amount we require.
▪ Leverage our vast network and relationships from past deals to
find the most suitable partners and consider multiple vendor
sourcing.
PRIORITIES
Assemble a team in charge of starting the
supplier screening considering our needs and
their capability to fulfill them.
The initial focus should be on:
▪ IT & Telco.
▪ Uniforms and linen
▪ Medical supplies
▪ Food procurement
Quicker impact in 
terms of cost savings.
1 2 Focus on our controlling
process, to improve our quality
overall.
▪ Set up an independent
controlling board constituted




Average annual savings €44M
(1) Planned savings on average purchase cost per bed and average external expenses per bed - more detail provided in Business Plan - Costs and EBITDAR Section and Appendix: Value Creation Strategy (2/2)
Impact of 1.2% in EBITDA 
mg.
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Value Creation Strategy | Real Estate Strategy
Korian should focus on the operation of its facilities, and reduce its asset base by taking advantage of Sale & Leaseback agreements.
Real Estate Portfolio
€1,280m
Our divestment process will take place along the 5 years of the
investment period and we expect it to be completed in 2022.
98 buildings
Given Korian’s partnerships with real estate operators (Cofinimmo,
Santé, Foncière des Murs) and previous sale and leaseback
transactions with them, this process should run smoothly.
OPTIMIZE REAL ESTATE STRATEGY
Korian can sell some real estate to fund its expansion strategy.
▪ Selling everything would put Korian in a risky position, as its fixed costs (rents) would increase significantly.
▪ Due to European economies’ uncertainty, we prefer to keep a robust real estate base to ensure Korian’s stability and provide flexibility in
case of an economic downturn.
keep EBITDAR above 1.5x Rental expensesTarget:Sell part of non-core Real Estate
Partnership since 2004.
French company specialized in leasing building in the European hotel 
sector. Leading player in commercial property.
Partnership since 2017.
Real estate player which designs innovative real estate products and 
services adapted to new urban lifestyles and habits. Icade is a significant 
player in the Greater Paris area and major French cities.
Partnership since 2008.
First listed Belgian real estate company specializing in rental property. 
Confinimmo supports healthcare operators in their growth and helps 
them to renovate and expand their facilities. One of the major real estate 
investors in the healthcare market in Europe.
Source: Company Reports
TAKING ADVANTAGE OF EXISTING PARTNERSHIPS
TIMELINE
To be able to service debt, pay tax and still invest in 
maintenance CAPEX, Korian needs to keep EBITDAR 
































Value Creation Strategy | Management to Implement the Strategy
Korian has the means to execute our strategy, although an investment in a strong M&A team is necessary and a CEO for Sweden must be recruited. 
CEO
Bossard has been working with Korian since
26 January 2016, Between 2012 and 2014, 
she was responsible for the SNCF group’s 
(railway company) strategy and development.
France 
Senior
Pinel has been with Korian since October 




Mérigot has been with Korian since October 
2016. From 2014 to 2016, he was CEO of 
Lavorel Group, a health care operator.
CEO for 
Germany
Schwalie has been with Korian since July 
2017. He has an extensive experience in the 
areas of hospitality and services, but has 
none regarding the Healthcare sector. 
CEO for 
Italy
Rossini works for Korian since 2007. She 
founded Segesta in 1995 and has been CEO 




Since 2005 the Senior Living Group’s CEO. 
Until 2014 in Korian, after merger with 




The group will need a CEO to take care of the Swedish 
division. Our suggestions are: Ulla Tanse, the current 
Head of Vardaga or Henrik Borelius the former CEO of 
Attendo.
CFO
Lemaire has been with Korian since 1st March 2016. 
Previously he was CFO of SOPRA STERIA GROUP and 
he also served  as a financial director for Danone.
HR
Boyer has been working with Korian since 1st
September 2016. Before he was VP Talents and Top 
Management of PSA Peugeot Citroën Group in 2015.
Quality
Armaingau has been working with Korian since 1st June 
2016 is a qualified doctor with a specialization in 
Gerontology. Before he was the Medical and Quality 




De Jessey joined the Korian Group in June 2017. She 
was the Communications Director for Gares et 




Durousseau has been working with Korian since 10th
October 2016. In 2014 he is appointed Chief 
Development Officer of Center Parcs Europe for the 
Pierre & Vacances Group. 
TBD Investment Team
Our high level of bolt-on acquisitions will require a dedicated M&A team. They will prospect the market, complete Due Dilligence
on the bolt-ons and carry negotiation processes. This team will have a full budget of €5 million per year, which includes salaries
and business expenses. This team will report to the BoD, and the Lisbon Capital Group will provide high-level support as
necessary.
34Investment Committee Paper January 25th, 2018
Business Plan
by Miguel Meco
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Business Plan | Operating Model
Investment focused on 2018/19, with correspondent growth and stabilization by 2022, and FCF generation 2.3x higher in 2022 vs 2017
2014A 2015A 2016A 2017E 2018E 2019E 2020E 2021E 2022E 5y CAGR
# of beds in operation 57 058 59 715 71 869 75 326 82 359 93 269 99 076 105 633 105 370 6,9%
% growth 5% 20% 5% 9% 13% 6% 7% 0%
CAPEX 142 212 549 45 528 290 136 131 49 
as a % of revenue 6% 8% 18% 1% 16% 7% 3% 3% 1%
Revenue 2 222 2 579 2 987 3 085 3 366 3 959 4 329 4 710 4 879 9,6%
% growth 16% 16% 3% 9% 18% 9% 9% 4%
EBITDAR 614 678 796 825 832 985 1 119 1 234 1 352 10,4%
% margin 28% 26% 27% 27% 25% 25% 27% 27% 28%
EBITDA 315 340 421 437 396 496 577 638 734 11,0%
% margin 14% 13% 14% 14% 12% 13% 13% 14% 15%
FCF before financing 115 51 -201 242 -181 146 374 426 566 18,5%
as a % of EBITDA 37% 15% -48% 55% -46% 29% 65% 67% 77%
Net Working Capital -89 -66 -73 -79 -81 -88 -88 -94 -88 2,2%








1. Growth in # of beds in operation mainly driven by smaller bolt-on acquisitions, but also from our investments in Sweden. We plan to increase the beds by 6,000 on average per year.
2. Revenue growth in line with network expansion, and driven also by solving staffing problem in Germany and price increases in France and Italy. Little growth in 2017 explained by the
decelerating expansion plan plus decreasing rates in the specialized clinics, which represent c. 30% of revenues in France and Italy. This decrease is expected to prevail until 2021.
3. EBITDAR margin will compress in the first years of the investment period given the ramp-up period of our investments accompanied by increasing personnel expenses. Once our initial
investments reach a mature state, the benefits of the multi-country contracts will prevail and the margin will increase.
4. Significant EBITDA margin compression in the first years given our bet in leasebacks, which will then reverse after new facilities become fully integrated.
5. Negative in 2018 (as in 2016) due to big acquisitions, then increases as expansion plan decelerates and real estate sales outweigh investments.
6. NWC will remain fairly constant as no optimization is expected.
7. CAPEX high in 2018 because of Vardaga, then decreases due to slowdown of expansion plan. In 2022 it just corresponds to maintenance CAPEX.
Values in M €
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Korian also has a mature network
in Belgium, so increases above the
current threshold will be minimal,


















Business Plan | Occupancy Rates
Korian has a mature network, and improvements will be focused in Germany with the mitigation of the staff shortage felt in that market.
Korian has a very mature network,

































Deficit in nurses is capping
occupancy rates. With our
initiatives, we expect it to increase
to 92% (+7% over 5 years, but still
3% below the average 95% of
other countries).
Strongest geography for Korian,
due to longer stays of patients.
Stable occupancy rate due to no
significant changes that can still be
implemented.
Occupancy rate estimated from
peers, no assumption is made






2014 2015 2016 2017 2018 2019 2020 2021 2022
Occupancy
Specialized Clinics (France and Italy) Mature network, so stable
occupancy rates of 95% according
to Korian’s IR.
Overall, we expect modest increases in occupancy rates, driven by Germany.















Korian can only set prices for additional
services in Belgium, so very low margin to
increase prices. Again, prices are only












Business Plan | Average Daily Rates
Korian has limited pricing power, as such improvements will be focused in France and Italy.
Korian can increase rates only on new
entrants, historically c. 1/3 of total
residents. In-line with current mgt.
expectations, this increase will be around
2% above inflation. Other residents are
indexed to public spending, which Korian
expects to translate into 0.5% increases
over the next years.
Daily Rate Improvement
(grey dash line is the price 
increasing with inflation)
Given the issuance of new licenses,
prices should be more competitive,
driving more modest increases in line with
inflation.
Note: Inflation forecasts of IMF, as of 27-Dec 
2017
According to Korian’s management,
Italy has margin to grow in daily rates
given that it is only present in regions
where rates are not capped, so new
patients should have similar growth in
rates to France.
Own Beds Outsourced BedsAverage
In line with our thesis, an increasing
percentage of beds in Sweden will be
owned, instead of outsourced. Given
the higher daily rate on the owned
model, we expect increases in the
average daily rate. Both the owned and
outsourced rates are varying with
inflation.
Given information provided by the
company, budget constraints will lead
to decreased rates in the order of 2-
2.5% over the next 3 years. After that,
we expect the market to rebound and
grow with inflation, which implies
average daily rates only slightly above
2016 levels













































Business Plan | Revenues
Revenue growth will be largely inorganic, but the different targeted geographies can help us diversify the risk of execution.
REVENUE GROWTH 58%
Organic Inorganic
Year-on-year growth 2018 2019 2020 2021 2022
Organic Growth 1.5% 4.6% 3.7% 2.8% 2.3%




▪ Average Daily Rates and Occupancy
➢ As explained in the previous slides, France and Italy will drive the price 
improvements while Germany will experience the only significant increase in 
occupancy rates, on an aggregate 10% of our forecasted revenue growth
▪ Standalone
➢ The beds Korian operates, plus the ones it is already building/restructuring, 
will drive an additional 17% growth, focused on the 2017-2020 period
▪ Bolt-on acquisitions
➢ The bulk of our revenue growth (56%), driving multiple arbitrage (5-7x small 
vs 10-15x largest operators), synergies and network expansion
▪ Vardaga
➢ The final pillar of our top-line expansion, the acquisition of Vardaga and the 
10 greenfields we plan to undertake in Sweden will contribute the final 17%
to our revenue growth – 13.6% generated by Vardaga itself and 3.4% 
derived from Greenfields
Values in M €
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Business Plan | Costs and EBITDAR









EBITDAR Margin per country






2017E 2018E 2019E 2020E 2021E 2022E
Revenues (M €) 3,085 3,366 3,959 4,329 4,710 4,879
COGS 248  266  295  316  341  345  
8.0% 7.9% 7.4% 7.3% 7.2% 7.1%
Personnel Expenses 1,541 1,757  2,086  2,258  2,446  2,487 
50.0% 52.2% 52.7% 52.2% 51.9% 51.0%
External Expenses 370  397  467  498  540  547  
12.0% 11.8% 11.8% 11.5% 11.5% 11.2%
Taxes and Duties 100  109  121  133  144  148 
3.2% 3.2% 3.1% 3.1% 3.1% 3.0%
EBITDAR 825 832  985  1,119  1,234  1,352  
As a % of Revenues 26.7% 24.7% 24.9% 25.8% 26.2% 27.7%
External Expenses: Multi-country contracts to obtain supplies and external services
Reduction applied to the average purchase cost per bed and to the average external
expenses per bed:
▪ 3% in 2018/19 to reflect the gradual process of implementing these contracts.
▪ 0.5% in 2020 through 2022 as opportunities in longer term arrangements arise.
▪ In Sweden this reduction was more aggressive: 6% in 2019 and 1.5% in 2020.
Personnel Expenses: No reduction in the cost per employee is expected, as it is
assumed to increase with inflation.
▪ In France and Italy the # of employees per bed will remain the same, 0.79 and 0.65
respectively.
▪ In Germany, due to the recruitment of personnel abroad, the # of employees per
bed will gradually increase from 0.44 to 0.5 (14% increase) aligned with the
occupancy rate (7%) increase.
▪ In Belgium, the current # of employees per bed is 0.82 which will be gradually
reduced to 0.75 as the recent acquisitions made (Foyer de Lork and OTV) become
completely integrated.
▪ In Sweden, Vardaga currently has 2.04 employees per bed, which will gradually
decline to 1.65. This high ratio can be explained by their difficulty in sharing
personnel resources between owned facilities and outsourced ones.
Taxes and duties reduced relative to revenue due to expansion to the Nordics.
These taxes refer to property taxes and licensing costs. In Sweden, companies are





COGS: Reduction mainly in Belgium and Italy, with COGS falling to 7% as network




Values in M €
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Business Plan | Network Expansion
Network will be expanded by 27,288 beds via acquisitions and greenfield investments with an investment of around € 830M.
Number of beds (2016) 2017 2018 2019 2020 2021
81,186 86,311 96,674 102,605 108,53881,186
71,869 in operation
9,317 in the pipeline*:
▪ 55% under construction
▪ 45% being restructured











Number of beds (2022)
108,474
Bolt-on acquisitions 






€ 613 M c. € 200 M € 16 M
Developed in Sweden under 
partnerships with real estate 
companies. We expect to start their 
construction in 2019.
Based on recent transactions, we believe we 
can buy Vardaga with a multiple of 10-12x 
EBITDA. We expect to complete the 
transaction by the end of 2018.
This type of transactions can be made 
at a multiple of 5-7x EBITDA.
(1) Plus 47 facilities that are already being constructed by Korian
In the regions where Korian is not 
present, profitability is limited due to  
regulation cap on prices. We will expand 
only in Lombardy, Veneto, Lazio and 
Apulia (current areas of operation)
Goal: become the #1 
player in Belgium. 
41Investment Committee Paper January 25th, 2018
EBITDAR/
Rents
France Germany Belgium Italy Total
2015 2.29 1.59 1.64 2.11 2.01
2016 2.33 1.93 1.69 2.24 2.12
2017E 2.24 1.89 1.58 1.86 2.02
Business Plan | Rents and Real Estate
Our Real Estate strategy focuses on retaining key properties, combined to balance-sheet/asset intensity optimization.
▪ Sell part of non-core real estate and lease it back.
▪ Leaseback 89% of the acquired facilities. Focus ownership in France and
Germany where the rental expenses are the highest.
▪ The 10 facilities we plan to construct in Sweden will be constructed under leasing
contracts.
Owned Buildings 75 11 1 11 98
Given the current valuation of Korian’s property (€1,280 M), on average each
facility can be sold by € 13 M.
Planned Sales 15 7 - 7 29
Gross Proceeds € 197 M € 90 M - € 90 M € 376.3
Net Proceeds € 145 M € 82 M - € 78 M € 314.5
Real Estate 
Market Data












Main assumption: In the case of the facilities that will be leased back, we assume we
will only support the cost relative to equipment and operations. The components
relative to land and buildings, and their development, will be supported by the real
estate companies with whom we have partnerships.










2015 2016 2017 2018 2019 2020 2021 2022 2023
EBITDAR/Rents - Group Level
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As a % of EBITDA
Business Plan | Cash Flows
The amount of FCF from Operations is on average 9.1% of revenues, although, it is based on an enormous investment in expansion.
167 214 266 304 376
147 162 166 171 167
2 6 1 6 (5)
(36) (39) (43) (46) (49)
279 343 391 435 489
8.3% 8.7% 9.0% 9.2% 10.0%
(227) (214) (86) (86) -
(48) (36) (8) - -
(217) - - - -
31 54 77 77 77







2018 2019 2020 2021 2022
(181) 146 374 426 566
(46%) 29% 65% 67% 77%
Note that, in this type of business, some cash is needed to provide some flexibility to the company to adapt quickly to changing regulation (e.g.: 
restructure facilities).






The company generates a good level of cash-flow from operations, although given our aggressive expansion strategy the FCF to service debt is negative in the
first year. Given the uncertainty of our investments and the time it takes for them to become rentable, a Revolving Credit Facility should be contracted to partially
fund the expansion plan, and provide us with some flexibility to service debt.
Values in M €
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Valuation and Capital 
Structure
by Miguel Meco
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0x 5x 10x 15x 20x 25x
LBO (IRR 19% to 27%)
DCF (Perpetual, T. Growth at 1% to
2.5%)









Valuation and Capital Structure | Valuation (1/3)
Considering all the valuation methodologies taken into account, we consider fair to offer a multiple of 11.5x EBITDA for Korian.
Valuation Methodology
In the valuation of Korian, it is important to distinguish between price and value. 
Price is the price we find reasonable to pay, and was determined through:
➢ Precedent Transactions: Comparing transactions in the Nursing Home space, 
only considering majority stake acquisitions and of an EV above €150m
➢ Trading Multiple (6 months and excl. acquisition premium): Korian’s
EV/EBITDA multiple, current EV dividend by 2017E EBITDA (consensus est.)
➢ Historical EV/EBITDA (5 years): Korian’s EV/EBITDA (next year) over last 5 
years
➢ Across-the-cycle comps EV/EBITDA (10 years): Comparables have historically 
traded above current levels, which points at 2017 being a good entry point in 
the industry
➢ NTM/LTM comps EV/EBITDA: EV/EBITDA trading multiples, in line with our 
current estimation for the acquisition
Value is the intrinsic return we expect to derive from this acquisition, derived through 
fundamental valuation:
➢ LBO implied IRR (19% to 27%): Taking the 10x-14x multiple range, we 
estimate IRR’s ranging from 19% to 27%, assuming exit in 2022, at multiple 
equal to entry
➢ DCF (Assuming Exit in 2022, Exit Multiple 10x-12x): Discounted Cash Flow 
Estimation, with WACC (excl. real estate debt) of 5.57% and exit multiple 
between 10x-12x (assuming minimal multiple expansion only in a best case 
scenario)
➢ DCF (Assuming Perpetual Ownership and Terminal g between 1 and 2.5%) 
Discounted Cash Flow Estimation, with WACC (excl. real estate debt) of 
5.57% and terminal growth estimation between 1% (conservative floor) and 
2.5% (in-line with current analyst estimates)
Football Field
Acquisition Multiple of 11.5x
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Valuation and Capital Structure | Valuation (2/3)
Trading Comps and Precedent transactions are roughly in-line, with Orpea’s superior growth potential driving the considerable premium



















Target Alloheim Domus VI SARquavitae Grupo Amma Sanyres Group Casa Reha Geriatros Domus Vi Curanum
Acquirer Nordic Capital Intermediate CG PAI Parterns Gr. Maisons Famille Orpea Korian PAI Parterns PAI Partners Korian
Date Announc. Dec/2017Jun/2017 Oct/2016 Jun/2016 Apr/2016 Nov/2015 Sep/2015 Jun/2014 Mar/2013
Country Germany France Spain Spain Spain Germany Spain France Germany
# beds 15,000 29,829 11,000 5,400 3,300 10,782 6,000 15,000 10,150
EV (€,m) 1,100.0 2,364.0 440.0 220.0 150.0 325.0 270.0 639.0 268.0
EV/Rev. - 1.8x 1.4x 2.3x 2.7x 1.2x 2.7x 1.0x 0.9x
EV/EBITDA 12.5x 13.1x 15.1x 12.2x 12.9x 10.8x 10.8x 9.7x 7.4x
Primary Comp EU Nursing Homes EU Specialized Clinics
11.5x
11.5x
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Valuation and Capital Structure | Valuation (3/3)
Run-rate EBITDA 2017E
Net Debt (million €)
Loans from credit institutions 1481.5
Real Estate Debt (excl. 
finance leases)
113.5
Unfunded Pension Liabilities 0.6
Bank Overdrafts 15.6
Other Financial Liabilities 290.1
Cash and cash equivalents 309.9





Assuming maturity of all nursing homes opened in 2017 (c. 1,360 beds). This value
is in line with the consensus estimate for Korian, which is around €436m.
Pipeline Adjustment
€45.3m
Given the pipeline size estimated at 7,957 beds1 (9,317 minus the 1,360 included
in the 2017 EBITDA) vs. 71,869 in operation, we will adjust this value, in order to
compensate Korian’s current shareholders for the amounts they have already
invested, and the remainder will be included in the CapEx forecasts in our model.
▪ Regarding Greenfields, we assume Korian has paid for 25% of the Greenfields
expected to open in 2018, and 0% for 2019.
▪ Regarding Restructurings, we are assuming the payments for 2018 were
already undertaken and for 2019 are done entirely by us.
It’s important to note that while these assumptions may have a significant impact in
the acquisition price, they will have insignificant impact on the returns of the
acquisition, since the higher the adjustment is, the lower the CapEx investment will
be.
1Estimation of Société Générale; 7,957 equals the 9,317 minus the 1,360 open in 2017 (and 
therefore included in the 2017 EBITDA)
Enterprise Value and Acquisition Price 
Note: Operating and Finance Leases are excluded from Net Debt calculations, as these are part of 


































EBITDA and adding the
rent expense, also at
run-rate.
EBITDAR Multiple based
on trading multiples for
Orpea and Attendo
Korian’s Enterprise Value is above €5bn, and an EBITDAR sense-check valuation confirms the equity price of c.€3.3bn
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Issue Type Issuer Rating Coupon Leverage
Senior Secured 
Notes
Voyage Care (‘17) B+ 5.86% 5.1x




Voyage Care (‘17) CCC+ 10.0% 6.1x
Four Seasons Health (‘12) B- 12.25% 5.0x
FRNs
Care UK (‘14) B LIBOR + 5% 4.4x
Care UK (‘14) CCC+ LIBOR + 7.5% 5.5x
Acquirer
Target
Year 2016 2014 2017 2017E
EBITDA mg 9.4% 9.7% 11.1% 14.1%
Leverage-to-EBITDA 6x 6.6x 7.25x 7.5x
▪ To support leverage 7.5x EBITDA, it will be required liquidity beyond the level that banks are willing to provide.
▪ Korian is already a bond issuer.
Valuation and Capital Structure | Debt Capital Market Analysis (1)
With BNP’s Leverage Finance team help, we looked at the options available in the market and the conditions we can obtain for each.
2. Recent Bond Issuance
In the absence of an official
credit rating, we are
assuming a single B rating for
Korian for the following
reasons:
▪ Highly levered business
▪ Aggressive financial
policy typical in private
equity ownership
1. Term Loans Market
▪ Given our aggressive expansion
strategy an amortizing structure would not
be advantageous in our case.
▪ Term Loans B, on average, are being
issued with a spread of 4%.
➢ Given the strong long-term
fundamentals of the senior care
sector, we believe we can obtain
a lower rate of 3.5% + EURIBOR.









Debt Structure: mix of term loans and bonds
Credit Rating
BNP’s Quotes
(1) Developed with the help and insight from BNP Paribas, therefore reflects current 
market stats.
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Valuation and Capital Structure | Proposed Capital Structure
After thorough analysis, we propose a Hybrid Bullet Senior and 2nd Lien Structure for a total debt package of €3,271M at 7.5x EBITDA.
Sources of Funds € M
x 
EBITDA




Senior debt Adjusted EBITDA ‘17 437.0
Term Loan B 1,000 2.3x 18.9% Entry Multiple 11.5x
Senior Secured Notes 527 1.2x 10.0% Enterprise Value 5,070 11.5x 95.7%
Floating Rate Notes 874 2.0x 16.5% Net Debt 1,745 4,0x 32.9%
Total Senior Debt 2,401 5.5x 45.4% Shares 3,325 7.6x 62.8%
Subordinated debt o/w Pipeline Adj. 45.3 0.1x 0.9%
Senior Unsecured Notes 874 2.0x 16.5%
Total debt 3,275 7.5x 61.8% Fees 228 0.5x 4.3%
Due Diligence Fees 51 0.1x 1.0%
Fixed Return Instrument 1,843 4.2x 34.8% Arrangement Fees 51 0.1x 1.0%




Sweet Equity (5%) 9 0,0x 0,2%
Total Equity 2,023 4.6x 38.2%
Total Sources 5,299 12.1x Total Uses 5,299 12.1x
Category Observations
Sources Debt: 
o Term Loan B (€): 7y 
o 3y Non-callable Senior Secured Notes (€): 7y
o 2y Non-callable Floating Rate Notes (€): 7y
o Revolving Credit Facility: 436M (undrawn), 6y
o 3y Non-callable Senior Unsecured Notes (€): 8y
Equity: 






▪ Term Loan B will bear annual interest rate of 3.50% plus EURIBOR.
o Will be repaid in a bullet payment at maturity (no prepayment penalty)
▪ Senior Secured Notes will have a coupon of 4% paid annually.
o Non-callable in the first 3 years, afterwards decreasing prepayment 
penalty. 
▪ Floating Rate Notes will have a coupon of 3.75% plus EURIBOR paid annually 
o Non-callable in the first 2 years, afterwards no prepayment penalty.
▪ RCF will bear annual interest rate of 3% plus a commitment fee of 1.05%.
o Must be fully repaid at maturity.
▪ Senior Unsecured Notes will have a coupon of 6.5% paid annually.
o Non-callable in the first 3 years, afterwards decreasing prepayment 
penalty.
▪ The FRI will bear interest rate equal to 12.5% (attributed to the PIK element).
o The repayment will take place in 9 years via a bullet payment.
Covenants TLB is Covenant Lite: no covenants. 
Incurrence covenants for Bonds: limitation on indebtedness and restricted 
payments. Change of control provisions are still under negotiation.
Syndicate 
Structure
Senior Debt will be issued through an Underwritten type of deal, whose total 
commitment (about €3.3B) will be guaranteed by the syndicate members. 
Underwriter fees are expected to be 2.5% of EV, while arrangement fess 1%.
Other Authorized issue of €700M of Senior Secured Notes, of which €174M will be held 
back for a tap issue if needed. 
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Transaction Structure













Co-Investment Partner BCo-Investment Partner A Management Team
Lisbon Capital Group 
Healthcare Fund
We believe a co-investment partner or partners can create
value for the fund due to 2 reasons:
▪ Lower risk, given the considerable size of this deal
▪ Approval seal for the fund
We will not relinquish control of Korian during our investment,
so we will necessarily remain majority shareholders.
However, we are willing to allow one or several partners to
invest in up to 49% of Korian’ Equity, under the exact same
conditions as the fund.
Co-investment Opportunity
*Given the considerable deal size, LCG will propose a co-investment opportunity to several partners, as outlined on the right
In terms of potential partners, the most natural candidates
are Korian’s current shareholders, in particular PSP
Investments. They have invested jointly in i) Kinetic
Concepts, a Medical Devices manufacturer acquired in a
$6.3b buyout in 2011; ii) Cerba HealthCare, an operator of
research laboratories acquired for €1.8b in 2017; which
makes us believe they would pose the ideal partner in this
acquisition.
After the current shareholders of Korian, we have shortlisted
several pension funds which could be co-investment
partners and have the necessary size for a deal of this
magnitude, namely i) the Quebec Deposit and Investment
Fund ii) the Canada Pension Plan Investment Board and iii)
CalPERS.
Co-investment Partners
Note: The management currently owns 388 shares, which represents 0.000485% of shares outstanding
Management Package
Given the very low number of
shares owned by management, we
have assumed no rollover.
The Management Team will be
requested to invest 2x their annual
salaries, at a total of € 9.0m.
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LBO Model and Exiting
by Maria Moreira











EV Cash RCF TLB SSN FRN SUN FRI Ords
▪ Cash Cover never goes below 1, although in the first year is tight due
to the high CAPEX needed for expansion. In 2022, it starts decreasing
because we start repaying the RCF, and it further decreases in 2023 due
to the inexistence of real estate sales in that year.
▪ Healthy Interest Cover Ratio, which increases gradually along the
investment period.
LBO Model | Returns
Our base case assumptions for the operating model and capital structure yield an IRR of 24% and a MoM of 2.9x for an exit in 2022.
▪ Management Team: it will enter with €9M for 5% of Ordinary Shares and
will receive by the exiting period €136M. This corresponds to an IRR of 72%
and a MoM of 15x.
▪ PE Fund: it will enter with €2,014M and by 2022, will be able to see its
equity stake on Korian worth €5,908M (€3,321M from the Sub Loan and
€2,586M of Ords). This corresponds to an IRR of 24% and a MoM of 2.9x.
Entry: With an entry multiple of 11.5x EBITDA and a run-rate EBITDA of €437M in 
2017, Korian is going to be acquired at an EV equal to €5,025M. Additional 
€45.3M will be paid to compensate the investment already undertaken by Korian 
for the beds that will open in 2018 and 2019.
Sale: Assuming no multiple arbitrage in this transaction, the company will be sold 




11x 19.3% 22.5% 20.8%
11.5x 21.4% 24.0% 21.9%















2,6 2,8 2,4 2,1





2018 2019 2020 2021 2022 2023
Interest Cover
Values in M €















LBO Model | Value Creation (1/2)
Equity growth mainly driven by Bolt-ons, which will generate more than € 2B contributing to c. 48% of the value created. 
Total Value Creation Cash Generation EBITDA Multiple Arbitrage Revenue Growth EBITDA Margin
4,294 = 876 + 0 + 2,923 + 495
Value Creation Contribution















Occ. Rate (4) and 
Price (5) Improv. Cost Savings
-0.35x -0.05x 1.01x 0.45x 0.65x 0.41x
Fees
Equity Bridge 
Notes: (2) 0.3x (3) 0.15x (4) 0.16x (5) 0.49xNote: (1) Value loss, although needed to help funding 
expansion and enable a 7.5x EBITDA leverage
Values in M €
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LBO Model | Value Creation (1/2)





Occ. Rate + Price 
Improv.
Cost Savings Real Estate Sales 2022
Revenue 3,085
3,385 (+300) 1,008 303 183 - - 4,879
+ 10% Our strategy will generate a growth of 48% in revenue. + 58%














Greenfields in the 
pipeline + annual 
increase of rental 
expense in line with 
inflation
Leasing contracts 
will be arranged for 
89% of acquired 
facilities
Leasing contracts 
will be arranged for 
all (10) greenfields 
in Sweden






EBITDA 437 335 (-102) +190 +81 +97 +60 -29 734
margin 14.1%
+ 9 bps
15.0%Expansion: COGS and External expenses will change from 
20.1% of sales to 18.3% and Taxes and duties’ from 3.2% to 3%
Compression: personnel expenses will change from 50% of 
sales to 51%, while rental expense from 12.6% to 12.7%
Values in M €














Lower Exit Multiple (9.5x)
Bonds must be redeemed at exit
Less public funding
Tighther regulation (+ restructurings per year)
Bolt-ons acquired at a higher multiple
Acquisition of just 50% of bolt-ons
Impossibility to acquire Vardaga
Higher employee costs
Higher rental expenses
Just 50% of planned cost savings
Impossibility to find required nurses for Germany
Price increases in France and Italy resulting in lower occ. rates
No greenfields in Sweden
LBO Model | Sensitivity Analysis of Returns
The major risks to our strategy are the impossibility to implement our expansion strategy, followed by higher personnel expenses.





1. COC provisions still under negotiation, although when business is sold to a
buyer with the same credit rating (e.g. another PE fund) bonds can usually be
transferred, avoiding this way the payment of penalties.
2. Keep updated regarding initiated debates so possible changes are
anticipated. Keep some cash on-hand to adapt quickly.
3
3. Strong M&A team to identify possible and attractive targets and ensure an
efficient implementation of the strategy. Pay a higher multiple if needed.
4
4. Assemble a team to approach the target and start negotiations, and also to
confirm the market’s attractiveness. Offering a higher price is also a
possibility: paying 15x EBITDA has an impact of -0,2% (base case: 11.5x).
5
5. Keep updated regarding regulatory issues and foment good relationships




7. Assemble a procurement team to start identifying the best suppliers and
manufacturers and start negotiations with them right away.
8. Assemble a team solely in charge of the conceptualization and
implementation of the recruitment process abroad. Consider also increasing
salaries: a 5% increase in the salary per employee results in an impact of -
1.1% in the IRR.
8
9. Keep facilities well-maintained and refurbished, so customers consider
price increase as “fair”.
9
6. Make an effort to keep the long-lasting relationships with real estate






































(1) Assumptions explained in the Appendix - LBO
Model section.
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LBO Model | Scenario Analysis
Only in the worst case scenario the fund incurs a loss, although we consider it very unlikely to happen as mitigation plans will be put in motion. 
Entry Exit IRR MoM
11.5x 9.5x 17.5% 2.24x
▪ Lower exit multiple
If bonds must be 
redeemed:




Entry Exit IRR MoM
11.5x 11.5x 9.7% 1.59x
▪ Acquisition of just 80% of the bolt-ons
▪ Vardaga acquired at higher multiple (13x vs 11.5x)
▪ Higher staff costs
▪ Higher rental expenses
▪ Just 50% of planned cost savings
▪ Impossibility to hire as many nurses for Germany as
initially planned
▪ Decreased occ. rate in France and Italy due to price
increases.
If bonds must be 
redeemed:
€ 786M in penalties
IRR MoM
5.2% 1.29x
OK but cash cover critical in Y1
Entry Exit IRR MoM
11.5x 9.5x -6,2% 0,73x
▪ Same as Bear B, but
▪ Acquisition of just 50% of the bolt-ons
▪ Impossibility to acquire Vardaga
▪ Impossibility to hire new nurses for Germany at all
▪ More restructurings per year due to tighter regulation
▪ Lower exit multiple
If bonds must be 
redeemed:




















































2018 2019 2020 2021 2022
(1) Bars - net debt/RR EBITDA; Line - cash cover
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Although we believe that the next few months will be a good entry point (5% discount to 10-year average), we see considerable economic uncertainty in the mid to long-term,
given ECB/FED tightening liquidity and budget deficits in the Eurozone potentially constraining social security programs, which leaves us skeptical of forecasting a multiple
expansion.
Rationale: In our opinion, an IPO represents the most feasible strategy due to
Korian’s market leader position in Europe. While IPOs have historically generated
the highest IRR returns, this trend has reverted over the last 5 years.
Downsides: It is highly market dependent, it is a long and expensive process; It
may require exiting in tranches, which is especially negative if we have to hold a
minority stake for a considerable period of time.
Mitigation: In our view, the two main drawbacks (Exit multiple dependent on
market conditions and long process) can be mitigated due to our Investment
Thesis remaining strong after our exit, i.e. Korian can still be a consolidator of a
fragmented industry, in a growing market, with high cash generation and strong
economies of scale; which can translate in a higher return upon exit.
LBO Model | Exit Strategy




Our Exit Strategy assumes that our exit multiple will be the same as our entry multiple: 11.5x
Rationale: Quickest and smoothest exit
strategy, and relatively cheap in terms of
transaction fees; Investment Thesis
remaining strong means PE appetite
would be high.
Downsides: The deal size (€ 8,357M)
would probably require multiple PE funds
to invest jointly, which reduces the
advantages of a Secondary Buyout, and
the liquidity in the market will also affect
market appetite for Korian.
Rationale: A trade sale tends to be
advantageous, as the buyer can
generate higher synergies and
therefore pay a higher multiple. Exit
also tends to only be done in full
Downsides: A strategic sale would
be transformational for the acquirer,
and due to the lack of larger players
in Senior Care, it would also imply
either Orpea or an Hospital
manager to be the acquirer.
2 3
Trade Sale
Our Exit strategy is focused on an IPO, followed by a Secondary Sale
An IPO would be our first option as we believe it represents the most suitable route to exit from such a big company, but based on market conditions also a Secondary Buyout
should be taken into account. Even if a strategic sale would be the most advantageous process for us, we do not believe in its feasibility because the only Health Care groups
big enough to acquire Korian do not operate in the Nursing Homes sector and do not have visible advantages to enter in that market.
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Due Diligence
by Maria Moreira
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Growth Outlook • Elderly care market outlook, with special focus on
countries where Korian operates
• Declines in adoption of professional nursing 
care





• Korian’s NH/SC portfolio analysis and comparison
to to nursing care providers on a region/area/city
level
• Concentration in highly-competitive areas
• Poor condition of the homes, or significantly less 
attractive than competitors
30 March 2018
Business Analysis • Deeper analysis of daily tariffs composition and
the pricing flexibility/outlook
• Focus on the comprehension of the profitability by
segment
• In-depth analysis of Germany’s staffing problem
• Daily Tariffs evolution
• Drivers of occupancy rates and potential points 
of improvement
• Bigger personnel deficiency than expected in 
Germany
30 March 2018
Acquisitions • Feasibility of acquiring the expected number of
facilities and attractiveness of Swedish market
• Valuation levels for bolt-on operators and
Vardaga
• Integration steps and potential synergies
• Process of acquisition lengthier than expected
• Valuation levels above Korian’s willingness to 
pay, or unfavorable market dynamics
• Integration process not allowing all acquisitions 










• License attribution for new NH and regulatory 
issues for the sector
• Conditions to open new NH in Sweden
• Atribution of new licenses in Korian’s countries 
of operation, leading to increased competition
• Feasibility of greenfields in Sweden
30 March 2018
Operations
• Public Contribution to Elderly Care
• Daily Rates
• Regulatory operating requirements
• Declining budgets for Elder Care providers, 
focus on public/non-profit operators, weighting 
on Daily Rates
• Increase in staffing or facility requirements
30 March 2018
Due Diligence (1/3)
Major red flag to verify assumptions for acquisitions as they materially impact our investment thesis.
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Accounting • Detailed Balance Sheet, P&L and Cash-flow
statement
• Profitability by type of home and individual home
• Run-rate EBITDA
• Working capital and Net Debt detailed analysis
• Accounting practices/policies
• Analysis of recent acquisitions consolidation
• Comparison to Business Plan assumptions
• Undisclosed figures significantly different from 
Business Plan assumptions
• Run-rate EBITDA below estimated
• Working Capital or Net Debt mismatch to fund’s 
valuation





• Property-by-property analysis, focus on rental
contracts and real estate optimization
• Verify market value of portfolio
• Conditions of the facilities and restructuring
needs to maintain quality standards, and implied
cost
• Change of control provisions, or particularly 
deteriorating and/or unprofitable terms for 
leased homes
• Comparison of Real Estate prices to rents for all 
areas where Korian operates
• Rental yields increasing sharply in medium-term
• More restructuring per year or at a higher cost
30 March 2018
Tax • Tax compliance, both on income taxes and taxes
for the operation of NH/SC
• Tax litigation/outstanding cases
• Transfer Pricing
• Tax liabilities above expected















• Independent detailed valuation, focus on cash 
generation, EBITDA and capital expenditures
• Review of completion mechanism and EBITDA, 
Working Capital and Net Debt adjustments
• Valuation levels materially different from LBO
30 March 2018
Exit
• Assessment of potential exit routes via trade-sale 
and secondary buyout, preliminary discussions 
with potential acquirers
• Low number of interested parties 
30 June 2018
Due Diligence (2/3)
It is crucial to analyze Korian’s real estate property and the current market conditions, to assess attractiveness of our real estate strategy. 
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• Individual assessment of core competencies, past
performance and individual areas of
strengthening
• Communication and analysis of management’s
view on investment thesis and management
package
• Management’s skills below market level
• Management unwilling to continue under PE 
ownership
• Management team not receptive to 
buyout/demanding incentives above reasonable
30 March 2018
New Hires • Potential experts for Elderly care in Sweden
• Suitable M&A team
• No quality candidates for the Vardaga post




Environment • Negative environmental impact of Korian’s
operations, focus on disposal of medical supplies
• Potential mitigation costs 
30 March 2018
Social • Assessment of Korian’s working and
compensation practices
• Analysis of existing relationships between Korian
and worker unions
• Deteriorating relationships and possibility of 
strikes/renegotiations of wages
• Unlawful working conditions
30 March 2018






• IT platform assessment of compatibility between 
locations and expandability to new houses
• Considerable costs of including potential 
acquisitions into IT system
30 March 2018
Logistics
• Logistics and supply chain analysis, focus on 
optimization with an expansion of the network
• Multi-country contracts
• Outdated logistics platform and inability to 
include new acquisitions seamlessly
• Unavailability of multi-country supply contracts, 
or no cost savings created
30 March 2018
Insurance
• Analysis of outstanding coverage and cost 
structure
• Low coverage or costs above market levels
30 March 2018
Due Diligence (3/3)
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Conclusion
After thorough analysis we can conclude that Korian is an attractive buy-out target operating in a very interesting sector.
Entry (2018)
Entry Multiple = 11.5x
Enterprise Value upon Entry = € 5,025M
Leverage will be up to 7.5x EBITDA 
▪ Mainly through a consolidation strategy with the increase of the number of beds in operation, on average, by 6k
per year. This will be achieved through 70-80 bolt-on acquisitions per year, and the expansion to Sweden, the biggest
Nordic market which currently has accentuated needs in terms of beds to be created in the next years (c. 4k beds per
year until 2030) and where private investment to construct new facilities is being incentivized to avoid inefficient
facilities in the outsourcing market.
▪ European senior care market spurred by 2.4% annual patient growth in the next 15 years and a rising demand for
care of chronic diseases, which will support our revenue CAGR17-22 of 10% (although, the contribution to growth from
pricing is limited). Revenue will also be enhanced by solving the staff shortage felt in last years in Germany, which has
been capping occupancy rates, with the implementation of a recruitment process abroad.
▪ We expect EBITDA margin to increase by 9bps to 15% due to the creation of multi-country contracts to obtain
supplies and external services for all facilities, which will generate significant cost savings (c. €44M per year), which
together with price and occupancy rate improvements, will offset the negative impact of the increased rental expenses
and of the expected increase in staff costs.
Exit (2022)
Most probable route: IPO
Expected Exit Multiple = 11.5x
Enterprise Value upon Exit = € 8,443M 




▪ Changes in insurance plans
▪ Media stories about unethical practices 
Operational Risks
▪ Difficulty to obtain licenses to open new facilities
▪ Changes in rental yields
▪ Wage inflation and staff shortage
▪ Inefficient integration of acquired facilities or 
inexistence of good targets
Regulatory/Political Risks
▪ Adverse or stricter Government policies
▪ The origin of Korian’s growth under the proposed
investment thesis will lie on strengthening the presence
in the markets where it is already present together with
the expansion to the Nordic market.
▪ As a consequence, this strategy will imply an
accentuated CAPEX, which will be followed by a margin
compression in the first years of the investment period,






Thank you for your 
attention!
Q&A
